VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

07 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

02 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

31 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

26 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

11 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

03 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

25 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

21 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Verrica Provides Business and Operational Update

20 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 Dec 2024 16:15:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

06 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Verrica Announces Pricing of $42.0 Million Public Offering

21 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Announces Proposed Public Offering

20 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

04 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

14 Aug 2024 07:45:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

14 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

06 Aug 2024 07:30:00 By Nasdaq GlobeNewswire